Skip to main content
Download PDF

Association of single nucleotide polymorphisms with insulin secretion, insulin sensitivity, and diabetes in women with a history of gestational diabetes mellitus

BMC Medical Genomics volume 14, Article number: 274 (2021) Cite this article

Abstract

Background

This study investigated whether single nucleotide polymorphisms (SNPs) reported by previous genome-wide association studies (GWAS) to be associated with impaired insulin secretion, insulin resistance, and/or type 2 diabetes are associated with disposition index, the homeostasis model assessment of insulin resistance (HOMA-IR), and/or development of diabetes following a pregnancy complicated by gestational diabetes mellitus (GDM).

Methods

Seventy-two SNPs were genotyped in 374 women with previous GDM from Southern Sweden. An oral glucose tolerance test was performed 1–2 years postpartum, although data on the diagnosis of diabetes were accessible up to 5 years postpartum. HOMA-IR and disposition index were used to measure insulin resistance and secretion, respectively.

Results

The risk A-allele in the rs11708067 polymorphism of the adenylate cyclase 5 gene (ADCY5) was associated with decreased disposition index (beta = − 0.90, SE 0.38, p = 0.019). This polymorphism was an expression quantitative trait loci (eQTL) in islets for both ADCY5 and its antisense transcript. The risk C-allele in the rs2943641 polymorphism, near the insulin receptor substrate 1 gene (IRS1), showed a trend towards association with increased HOMA-IR (beta = 0.36, SE 0.18, p = 0.050), and the T-allele of the rs4607103 polymorphism, near the ADAM metallopeptidase with thrombospondin type 1 motif 9 gene (ADAMTS9), was associated with postpartum diabetes (OR = 2.12, SE 0.22, p = 0.00055). The genetic risk score (GRS) of the top four SNPs tested for association with the disposition index using equal weights was associated with the disposition index (beta = − 0.31, SE = 0.29, p = 0.00096). In addition, the GRS of the four SNPs studied for association with HOMA-IR using equal weights showed an association with HOMA-IR (beta = 1.13, SE = 0.48, p = 9.72874e−11). All analyses were adjusted for age, body mass index, and ethnicity.

Conclusions

This study demonstrated the genetic susceptibility of women with a history of GDM to impaired insulin secretion and sensitivity and, ultimately, to diabetes development.

Peer Review reports

Background

During pregnancy, insulin sensitivity progressively decreases, while associated insulin response increases by late gestation [1]. Gestational diabetes mellitus (GDM) develops when beta-cells cannot compensate for increased insulin resistance, despite the physiological changes related to glucose homeostasis during gestation [1]. Women with a history of GDM have a higher risk of developing type 2 diabetes [2] and metabolic syndrome [3] than those who were normoglycaemic during pregnancy. Genetic risk factors related to progression to type 2 diabetes in women with a history of GDM have been previously studied by many research groups, including ours. Two polymorphisms (TCF7L2 rs7903146 and FTO rs8050136) and a weighted risk score of type 2 diabetes risk alleles predict diabetes following GDM [4]. Other research groups have shown an association of the genetic risk score (GRS) with eventual progression to diabetes after GDM [5]. However, GRS could not predict the progression to diabetes in women with a history of GDM from the Diabetes Prevention Program (DPP) [6].

Type 2 diabetes is a growing global health concern and is caused by insulin resistance and beta-cell dysfunction [7]. Recent evidence suggests that both insulin secretion and resistance are heritable traits [8] and studies have also demonstrated a genetic contribution to defective insulin secretion and resistance in individuals with type 2 diabetes [9, 10].

Genome-wide association studies (GWAS) have revealed many genetic susceptibility loci for type 2 diabetes and related traits, such as insulin resistance and beta-cell dysfunction [10,11,12,13,14,15]. In addition, we have recently shown an association of the rs11708067 polymorphism in the ADCY5 (adenylate cyclase 5) gene with increased 2-h glucose levels and decreased homeostasis model assessment of beta-cell function (HOMA2-B) in Swedish women with GDM [16].

Only a few studies have examined the genetic susceptibility to postpartum diabetes in women with previous GDM [4, 17]. In addition, the genetic architecture of postpartum diabetes and its related traits could differ between ethnicities. Thus, we sought to validate the association of single nucleotide polymorphisms (SNPs) from previous GWAS [10,11,12,13,14,15, 18] with indices of beta-cell function, insulin resistance, and eventual progression to diabetes in a cohort of women from Southern Sweden with a history of GDM. The association of genetic variation with a phenotype can be mediated by gene expression in the target tissues. Such loci, which can explain the variation in the mRNA levels, are referred to as expression quantitative trait loci (eQTLs) [19]. Therefore, we aimed to examine whether the eventual associated SNPs were also eQTLs in the RNA-Seq data from 191 human pancreatic donor islets [20] as well as insulin target tissues from the Genotype-Tissue Expression project (GTEx) [21].

Methods

Participants

Women delivering between 2003 and 2005 were invited to participate in the study in the County of Skane in Southern Sweden, as described previously [22]. GDM was diagnosed by a 75-g oral glucose tolerance test (OGTT) at the 28th and/or the 12th week of gestation for those with a first-degree relative with diabetes or previous GDM. Study participants were followed-up for development of diabetes using OGTT up to 5 years postpartum or until a diagnosis of diabetes; data were accessible through the primary care journals. GDM and diabetes were diagnosed according to the diagnostic criteria recommended by the WHO in 1999 [23]. Based on these criteria and the availability of stored DNA, a cohort of 374 women with previous GDM (57 of whom developed diabetes) were included in the present study.

Glycaemic trait measurements

Women underwent OGTT with measurements of both glucose and insulin concentrations at 0, 30, and 120 min to calculate indices of beta-cell function and insulin resistance, at 1‒2 years postpartum, as reported previously [24]. Homeostasis model assessment of insulin resistance (HOMA-IR) was used to estimate insulin resistance (fasting serum insulin × fasting plasma glucose)/22.5 [25]. Insulin secretion capacity was estimated using the disposition index ([insulinogenic index (insulin 30 min – insulin 0 min)/(glucose 30 min − glucose 0 min)]/HOMA-IR) [26].

Genotyping

DNA was extracted from whole blood using the MaxiPrep Kit (QIAGEN, Sollentuna, Sweden). SNPs were genotyped using a Sequenom massARRAY platform or TaqMan allelic discrimination assay with an ABI Prism 7900 sequence detection system (Applied Biosystems, Foster City, CA, USA). The success rate of genotyping was > 90%. Replication genotyping of 6% of the samples showed > 98% concordance. All SNPs were in Hardy–Weinberg equilibrium (HWE), except for rs11920090 and rs6467136, which significantly deviated in women who did not develop diabetes postpartum (p < 0.01), and were eventually excluded from the analysis. We analysed 12 SNPs previously shown to be associated with measures of insulin secretion [11, 12, 14], and 4 SNPs previously shown to be associated with measures of insulin resistance in GWAS [10, 11, 13], for association with disposition index and HOMA-IR, respectively, in women with previous GDM. We also analysed 70 (2 out of 72 were excluded for not being in HWE) SNPs, previously associated with diabetes in GWAS [11, 15, 18], for association with diabetes postpartum.

Exploration of expression quantitative trait loci (eQTLs)

Polymorphisms associated with disposition index, HOMA-IR, or diabetes were assessed for association with gene expression in human pancreatic islets in RNA-Seq data of 191 donors [19] or insulin target tissues from GTEx [20]. The data are uploaded to EGA (https://ega-archive.org/) with the following accession numbers: RNAseq: EGAS00001004042, GWAS: EGAS00001004044, and Phenotype: EGAS00001004056.

Statistical analyses

All statistical analyses were conducted using IBM SPSS Statistics for Windows, version 22.0 (Armonk, NY) and PLINK (version 1.09, http://pngu.mgh.harvard.edu/~purcell/plink/index.shtml). Categorical variables are shown as N. They are presented as mean ± standard deviation (SD). Student's t-test was used to test for differences between group means. Generalised linear models with maximum likelihood estimates were used for estimating SNP associations with disposition index and HOMA-IR. Logistic regression models were used for SNP associations with diabetes. Age, ethnicity, and body mass index (BMI) were used as covariates/confounders, and data are presented as beta estimates and standard errors (SE). Correction for multiple testing was performed using permutations. We applied a false discovery rate (FDR) for the association analysis of postpartum diabetes. Since it was a validation of previous associations, we considered p ≤ 0.05 as significant. The top 4 SNPs associated with the disposition index and the 4 SNPs tested for association with HOMA-IR were used to construct Genetic Risk Scores (GRS) [27] for their respective traits as well as for diabetes using equal weights.

Results

Clinical characteristics

Clinical characteristics of the study subjects were detailed previously [28]. Table 1 presents some of the relevant clinical characteristics of the studied women. The women who developed diabetes postpartum were older (Mean = 34.61, SD 4.76 vs. 32.56, SD 4.77, p = 0.003), had a higher BMI (Mean = 30.48, SD 6.15 vs. 24.29, SD 4.43, p < 0.0001), lower disposition index (Mean = 3.00, SD 6.62 vs. 9.00, SD 15.27, p = 0.0038), and higher HOMA-IR (Mean = 2.56, SD 3.32 vs. 0.34, SD 3.70, p < 0.0001) compared to those without postpartum diabetes.

Table 1 Clinical characteristics of the studied women
Full size table

Association of SNPs with disposition index

The risk A-allele of SNP rs11708067 in the ADCY5 locus was associated with decreased disposition index (beta = − 0.90, SE 0.38, p = 0.019) after adjustment for age, BMI, and ethnicity (Table 2). Interestingly, the rs11708067 polymorphism was an eQTL for both ADCY5 and the antisense transcript for ADCY5 (Table 3). The ADCY5 rs11708067 genotype was also associated with 2-h glucose level, though only in the additive model (AG vs. GG: beta = 0.62, SE 0.33, p = 0.06; AA vs. GG: beta = 0.71, SE 0.32, p = 0.027).

Table 2 Association of SNPs with disposition index at 1–2 years postpartum in women previous GDM
Full size table
Table 3 rs11708067 is an eQTL for ADCY5 and the antisense transcript of ADCY5 in islets
Full size table

Association of SNPs with HOMA-IR

The risk C-allele of the insulin receptor substrate-1 (IRS1) rs2943641 polymorphism showed a trend towards association with increased HOMA-IR (beta = 0.36, SE 0.18, p = 0.050) after adjustment for age, BMI, and ethnicity (Table 4). A search of this SNP in the GTEx database (from public data [https://gtexportal.org/]) [20] showed that this SNP is an eQTL for IRS1 in the adipose tissue (normalised effect size in sub-cutaneous adipose tissue for the C allele = − 0.3, p = 1–4e−16 and normalised effect size in visceral adipose tissue for the C allele = − 0.23, p = 6.1e−12).

Table 4 Association of SNPs with HOMA-IR at 1–2 years postpartum in women with previous GDM
Full size table

Association studies of diabetes postpartum

The T-allele of rs4607103, near the ADAM metallopeptidase with thrombospondin type 1 motif 9 (ADAMTS9) gene, was associated with an increased risk of diabetes postpartum (OR for the C-allele 0.47 (CI: 0.30–0.73), p = 0.00055; pFDR = 0.039) (Table 5). The CC carriers have more insulin resistance than TT carriers (beta = − 0.11, SE = 0.05, p = 0.036).

Table 5 SNPs with nominal p-values for association with diabetes up to 5 years after a pregnancy complicated by GDM
Full size table

Association studies of generic risk scores (GRSs)

The GRS of the top four SNPs (ADCY5 rs11708067, MADD rs7944584, CRY2 rs11605924, and CDKAL1 rs7756992) among 12 SNPs tested for association with the disposition index (Table 2) [29,30,31,32] using equal weights was associated with the disposition index (beta = − 0.31, SE = 0.29, p [adjusted for age, BMI, and ethnicity] = 0.00096; p for diabetes [no covariates] = 0.81).

The GRS of the four SNPs studied for association with HOMA-IR (IRS1 rs2943641, IRS1 rs4675095, PPARG rs1801282, and IGF1 rs35767) (Table 4) [10, 11, 33, 34] using equal weights showed an association with HOMA-IR (beta = 1.13, SE = 0.48, p [adjusted for age, BMI, and ethnicity] = 9.72874e−11; p for diabetes [no covariates] = 0.63).

Discussion

In this study, we examined the genetic susceptibility of the genetic risk loci from previous GWAS with disposition index, HOMA-IR, and the development of postpartum diabetes in women with previous GDM from Southern Sweden. Women with previous GDM who developed postpartum diabetes had a higher HOMA-IR and a lower disposition index compared to those without postpartum diabetes. We found an association between the risk A-allele of ADCY5 rs11708067 and decreased disposition index derived from OGTT at 1–2 years postpartum in women with previous GDM. This was concordant with previous findings of an association of rs11708067 with HOMA-B, a measure of insulin secretion [11]. ADCY5 encodes adenylate cyclase 5, which catalyses the generation of cAMP. When glucagon-like peptide 1 (GLP-1) binds to its receptor in the pancreatic beta cells, it induces cAMP-mediated activation of protein kinase A, transcription of the proinsulin gene, and secretion of insulin [35]. Previous studies reported reduced ADCY5 mRNA expression in islets due to risk alleles at rs11708067 [29] and suggested that ADCY5 rs11708067 is essential for coupling glucose to insulin secretion in human islets [29]. Wagner et al. implicated the rs11708067 polymorphism in defective proinsulin-to-insulin conversion [36]. Furthermore, rs11708067 is an eQTL in islets for both ADCY5 and the antisense transcript for ADCY5 supports the role of this SNP in impairment of insulin secretion in women with previous GDM, thus increasing the risk of diabetes postpartum. We also found that the ADCY5 rs11708067 genotype was associated with 2-h glucose level, consistent with the previous results from our group [16] as well as others [11, 36].

Our analysis also identified an association of the risk C-allele of rs2943641 near the IRS1 gene with HOMA-IR in our cohort. IRS1 encodes a member of the IRS protein substrate family. IRS1 is a substrate of the insulin receptor tyrosine kinase, which plays a crucial role in the insulin signalling pathway and is expressed in insulin-sensitive tissues [37]. This finding agrees with an earlier study by Rung et al., who reported an association of the C-allele of rs2943641 with measures of insulin resistance (HOMA-IR and Insulin sensitivity index [ISI]) and hyperinsulinemia in French, Danish, and Finnish participants from population-based cohorts [10]. Moreover, this SNP has been associated with type 2 diabetes in meta-analyses involving European [10] and Japanese participants [38]. Notably, rs2943641 is an eQTL for the IRS1 gene in adipose tissue. Thus, this genetic variant near IRS1 may increase the risk of postpartum diabetes in women with previous GDM through increased insulin resistance.

We have shown that the T-allele of rs4607103, near the ADAMTS9 gene, could predict development of diabetes in our cohort. However, the risk allele in this study was opposite to that reported for diabetes [15]. ADAMTS9 is a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) protein family. It is highly expressed in various tissues and is abundantly expressed in the heart and skeletal muscle [39]. Graae et al. showed that the C-allele was associated with increased expression of secreted ADAMTS9 and decreased insulin sensitivity and signalling in human skeletal muscle [40]. In contrast, in our data CC carriers seemed to have reduced insulin resistance compared to TT carriers, although there was no significant association. This phenomenon is not uncommon in genetics [41]; the actual functional variant in the ADAMTS9 region is not yet known, and the rs4607103 polymorphism may be in a linkage disequilibrium with the functional variant in this region. Interestingly, the C-allele was associated with protection from type 2 diabetes in African Americans [42], but our study population was primarily European. Moreover, a potential gender effect could not be excluded [43]. We do not have any data on the presence of antibodies in women who developed diabetes postpartum. Since approximately 1% of women with diabetes postpartum are diagnosed with type 1 diabetes in Sweden [44], the vast majority of women included in this study were expected to have been diagnosed with type 2 diabetes.

Finally, we also tested the association of GRS with insulin secretion and resistance as well as postpartum diabetes. A GRS is an estimate of the cumulative contribution of genetic factors to a specific outcome of interest in an individual [27]. In our study, the GRS for disposition index and HOMA-IR was constructed from 4 SNPs associated with their respective traits. The GRS predicted variations in both traits. However, these GRS were not independently associated with diabetes, which could potentially be attributed to low statistical power. Recent studies showed heterogeneity of type 2 diabetes and GDM with insulin secretion driven subtypes being different compared to insulin resistance driven subtypes [45,46,47]. The lack of association could also be attributed to this potential heterogeneity which would require further research. Overall, the results of this study illustrate the crucial role of defective insulin secretion and impaired insulin sensitivity in women with previous GDM who develop postpartum diabetes, and how genetic risk factors could be used to identify these women. Our results and potential future studies in other populations might help to identify clinical and genetic risk profile(s) that could provide an early and appropriate preventive strategy for this high-risk group.

A strength of this study was the use of the disposition index, derived from OGTT, as a measure of beta-cell function adjusted for insulin resistance. The women in the study were followed up for development of diabetes up to 5 years postpartum. Our study provides novel insights into the genetic variants associated with postpartum diabetes and its related traits. A major weakness of the study was the failure to correct for multiple comparisons in the analyses, except for the analysis of development of diabetes after pregnancy. However, the analyses were adjusted for age, BMI, and ethnicity; permutations were performed to address this issue to a certain extent. The studied SNPs were previously shown to be associated with their respective traits, suggesting that this study could be considered a replication study. The study did not aim to detect small potential effects of the studied SNPs on insulin secretion and sensitivity.

Conclusions

The current study demonstrates the genetic susceptibility for impaired insulin secretion and sensitivity, as well as for the development of diabetes in women with a history of GDM. This finding could aid in the early identification of women at higher risk of developing diabetes postpartum.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Abbreviations

ADAMTS9 :

ADAM metallopeptidase with thrombospondin type 1 motif 9 gene

ADCY5 :

Adenylate cyclase 5 gene

BMI:

Body mass index

eQTL:

Expression quantitative trait loci

FDR:

False discovery rate

GDM:

Gestational diabetes mellitus

GLP-1:

Glucagon-like peptide 1

GRS:

Genetic risk score

GTEx:

Genotype-Tissue Expression project

GWAS:

Genome-wide association studies

HOMA2-B:

Homeostasis model assessment of beta-cell function

HOMA-IR:

Homeostasis model assessment of insulin resistance

IRS1 :

Insulin receptor substrate 1

ISI:

Insulin sensitivity index

OGTT:

Oral glucose tolerance test

SNP:

Single nucleotide polymorphisms

References

  1. 1.

    Catalano PM. Trying to understand gestational diabetes. Diabet Med. 2014;31(3):273–81.

    PubMed  PubMed Central  CAS  Google Scholar 

  2. 2.

    Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet. 2009;373(9677):1773–9.

    PubMed  CAS  Google Scholar 

  3. 3.

    Lauenborg J, Mathiesen E, Hansen T, Glumer C, Jorgensen T, Borch-Johnsen K, et al. The prevalence of the metabolic syndrome in a danish population of women with previous gestational diabetes mellitus is three-fold higher than in the general population. J Clin Endocrinol Metab. 2005;90(7):4004–10.

    PubMed  CAS  Google Scholar 

  4. 4.

    Ekelund M, Shaat N, Almgren P, Anderberg E, Landin-Olsson M, Lyssenko V, et al. Genetic prediction of postpartum diabetes in women with gestational diabetes mellitus. Diabetes Res Clin Pract. 2012;97(3):394–8.

    PubMed  CAS  Google Scholar 

  5. 5.

    Li M, Rahman ML, Wu J, Ding M, Chavarro JE, Lin Y, et al. Genetic factors and risk of type 2 diabetes among women with a history of gestational diabetes: findings from two independent populations. BMJ Open Diabetes Res Care. 2020;8(1):e000850.

    PubMed  PubMed Central  Google Scholar 

  6. 6.

    Sullivan SD, Jablonski KA, Florez JC, Dabelea D, Franks PW, Dagogo-Jack S, et al. Genetic risk of progression to type 2 diabetes and response to intensive lifestyle or metformin in prediabetic women with and without a history of gestational diabetes mellitus. Diabetes Care. 2014;37(4):909–11.

    PubMed  PubMed Central  CAS  Google Scholar 

  7. 7.

    DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015;1:15019.

    PubMed  Google Scholar 

  8. 8.

    Poulsen P, Levin K, Petersen I, Christensen K, Beck-Nielsen H, Vaag A. Heritability of insulin secretion, peripheral and hepatic insulin action, and intracellular glucose partitioning in young and old Danish twins. Diabetes. 2005;54(1):275–83.

    PubMed  CAS  Google Scholar 

  9. 9.

    Lyssenko V, Nagorny CL, Erdos MR, Wierup N, Jonsson A, Spegel P, et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet. 2009;41(1):82–8.

    PubMed  CAS  Google Scholar 

  10. 10.

    Rung J, Cauchi S, Albrechtsen A, Shen L, Rocheleau G, Cavalcanti-Proenca C, et al. Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. Nat Genet. 2009;41(10):1110–5.

    PubMed  CAS  Google Scholar 

  11. 11.

    Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet. 2010;42(2):105–16.

    PubMed  PubMed Central  CAS  Google Scholar 

  12. 12.

    Steinthorsdottir V, Thorleifsson G, Reynisdottir I, Benediktsson R, Jonsdottir T, Walters GB, et al. A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet. 2007;39(6):770–5.

    PubMed  CAS  Google Scholar 

  13. 13.

    Diabetes Genetics Initiative of Broad Institute of H, Mit LU, Novartis Institutes of BioMedical R, Saxena R, Voight BF, Lyssenko V, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science. 2007;316(5829):1331–6.

  14. 14.

    Prokopenko I, Langenberg C, Florez JC, Saxena R, Soranzo N, Thorleifsson G, et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet. 2009;41(1):77–81.

    PubMed  CAS  Google Scholar 

  15. 15.

    Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T, et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet. 2008;40(5):638–45.

    PubMed  PubMed Central  CAS  Google Scholar 

  16. 16.

    Arora GP, Akerlund M, Brons C, Moen GH, Wasenius NS, Sommer C, et al. Phenotypic and genotypic differences between Indian and Scandinavian women with gestational diabetes mellitus. J Intern Med. 2019;286(2):192–206.

    PubMed  CAS  Google Scholar 

  17. 17.

    Kwak SH, Choi SH, Kim K, Jung HS, Cho YM, Lim S, et al. Prediction of type 2 diabetes in women with a history of gestational diabetes using a genetic risk score. Diabetologia. 2013;56(12):2556–63.

    PubMed  Google Scholar 

  18. 18.

    Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet. 2010;42(7):579–89.

    PubMed  PubMed Central  CAS  Google Scholar 

  19. 19.

    Das SK, Sharma NK. Expression quantitative trait analyses to identify causal genetic variants for type 2 diabetes susceptibility. World J Diabetes. 2014;5(2):97–114.

    PubMed  PubMed Central  Google Scholar 

  20. 20.

    Asplund OPS, Emilia Ottosson-Laakso, Ulrika Krus, Olle Korsgren, Hindrik Mulder, Erik Renstrom, Ola Hansson, Leif Groop, Rashmi B Prasad. Islet Gene View - a tool to facilitate islet research. bioRxiv. 2019;https://doi.org/10.1101/435743v2.full. Accessed 2 November 2021.

  21. 21.

    Consortium GT. The genotype-tissue expression (GTEx) project. Nat Genet. 2013;45(6):580–5.

    Google Scholar 

  22. 22.

    Anderberg E, Landin-Olsson M, Kalen J, Frid A, Ursing D, Berntorp K. Prevalence of impaired glucose tolerance and diabetes after gestational diabetes mellitus comparing different cut-off criteria for abnormal glucose tolerance during pregnancy. Acta Obstet Gynecol Scand. 2011;90(11):1252–8.

    PubMed  Google Scholar 

  23. 23.

    World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications : report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus. World Health Organization. 1999.

  24. 24.

    Ignell C, Shaat N, Ekelund M, Berntorp K. The impact of ethnicity on glucose homeostasis after gestational diabetes mellitus. Acta Diabetol. 2013;50(6):927–34.

    PubMed  CAS  Google Scholar 

  25. 25.

    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.

    PubMed  CAS  Google Scholar 

  26. 26.

    Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE, American Diabetes Association GSG. Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S. Diabetes. 2002;51(7):2170–8.

  27. 27.

    Igo RP Jr, Kinzy TG, Cooke Bailey JN. Genetic Risk Scores. Curr Protoc Hum Genet. 2019;104(1):e95.

    PubMed  PubMed Central  Google Scholar 

  28. 28.

    Shaat N, Ignell C, Katsarou A, Berntorp K. Glucose homeostasis, beta cell function, and insulin resistance in relation to vitamin D status after gestational diabetes mellitus. Acta Obstet Gynecol Scand. 2017;96(7):821–7.

    PubMed  CAS  Google Scholar 

  29. 29.

    Hodson DJ, Mitchell RK, Marselli L, Pullen TJ, Gimeno Brias S, Semplici F, et al. ADCY5 couples glucose to insulin secretion in human islets. Diabetes. 2014;63(9):3009–21.

    PubMed  PubMed Central  Google Scholar 

  30. 30.

    Li LC, Wang Y, Carr R, Haddad CS, Li Z, Qian L, et al. IG20/MADD plays a critical role in glucose-induced insulin secretion. Diabetes. 2014;63(5):1612–23.

    PubMed  PubMed Central  CAS  Google Scholar 

  31. 31.

    Stamenkovic JA, Olsson AH, Nagorny CL, Malmgren S, Dekker-Nitert M, Ling C, et al. Regulation of core clock genes in human islets. Metabolism. 2012;61(7):978–85.

    PubMed  CAS  Google Scholar 

  32. 32.

    Okamura T, Yanobu-Takanashi R, Takeuchi F, Isono M, Akiyama K, Shimizu Y, et al. Deletion of CDKAL1 affects high-fat diet-induced fat accumulation and glucose-stimulated insulin secretion in mice, indicating relevance to diabetes. PLoS ONE. 2012;7(11):e49055.

    PubMed  PubMed Central  CAS  Google Scholar 

  33. 33.

    Hara K, Tobe K, Okada T, Kadowaki H, Akanuma Y, Ito C, et al. A genetic variation in the PGC-1 gene could confer insulin resistance and susceptibility to Type II diabetes. Diabetologia. 2002;45(5):740–3.

    PubMed  CAS  Google Scholar 

  34. 34.

    Ingelsson E, Langenberg C, Hivert MF, Prokopenko I, Lyssenko V, Dupuis J, et al. Detailed physiologic characterization reveals diverse mechanisms for novel genetic Loci regulating glucose and insulin metabolism in humans. Diabetes. 2010;59(5):1266–75.

    PubMed  PubMed Central  CAS  Google Scholar 

  35. 35.

    Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest. 2007;117(1):24–32.

    PubMed  PubMed Central  CAS  Google Scholar 

  36. 36.

    Wagner R, Dudziak K, Herzberg-Schafer SA, Machicao F, Stefan N, Staiger H, et al. Glucose-raising genetic variants in MADD and ADCY5 impair conversion of proinsulin to insulin. PLoS ONE. 2011;6(8):e23639.

    PubMed  PubMed Central  CAS  Google Scholar 

  37. 37.

    Boucher J, Kleinridders A, Kahn CR. Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb Perspect Biol. 2014;6(1):a009191.

    PubMed  PubMed Central  Google Scholar 

  38. 38.

    Ohshige T, Iwata M, Omori S, Tanaka Y, Hirose H, Kaku K, et al. Association of new loci identified in European genome-wide association studies with susceptibility to type 2 diabetes in the Japanese. PLoS ONE. 2011;6(10):e26911.

    PubMed  PubMed Central  CAS  Google Scholar 

  39. 39.

    Clark ME, Kelner GS, Turbeville LA, Boyer A, Arden KC, Maki RA. ADAMTS9, a novel member of the ADAM-TS/ metallospondin gene family. Genomics. 2000;67(3):343–50.

    PubMed  CAS  Google Scholar 

  40. 40.

    Graae AS, Grarup N, Ribel-Madsen R, Lystbaek SH, Boesgaard T, Staiger H, et al. ADAMTS9 regulates skeletal muscle insulin sensitivity through extracellular matrix alterations. Diabetes. 2019;68(3):502–14.

    PubMed  PubMed Central  CAS  Google Scholar 

  41. 41.

    Lin PI, Vance JM, Pericak-Vance MA, Martin ER. No gene is an island: the flip-flop phenomenon. Am J Hum Genet. 2007;80(3):531–8.

    PubMed  PubMed Central  CAS  Google Scholar 

  42. 42.

    Cooke JN, Ng MC, Palmer ND, An SS, Hester JM, Freedman BI, et al. Genetic risk assessment of type 2 diabetes-associated polymorphisms in African Americans. Diabetes Care. 2012;35(2):287–92.

    PubMed  PubMed Central  CAS  Google Scholar 

  43. 43.

    Khramtsova EA, Davis LK, Stranger BE. The role of sex in the genomics of human complex traits. Nat Rev Genet. 2019;20(3):173–90.

    PubMed  CAS  Google Scholar 

  44. 44.

    Dereke J, Nilsson C, Strevens H, Landin-Olsson M, Hillman M. IgG4 subclass glutamic acid decarboxylase antibodies (GADA) are associated with a reduced risk of developing type 1 diabetes as well as increased C-peptide levels in GADA positive gestational diabetes. Clin Immunol. 2016;162:45–8.

    PubMed  CAS  Google Scholar 

  45. 45.

    Huvinen E, Eriksson JG, Stach-Lempinen B, Tiitinen A, Koivusalo SB. Heterogeneity of gestational diabetes (GDM) and challenges in developing a GDM risk score. Acta Diabetol. 2018;55(12):1251–9.

    PubMed  CAS  Google Scholar 

  46. 46.

    Powe CE, Hivert MF, Udler MS. defining heterogeneity among women with gestational diabetes mellitus. Diabetes. 2020;69(10):2064–74.

    PubMed  PubMed Central  CAS  Google Scholar 

  47. 47.

    Ahlqvist E, Storm P, Karajamaki A, Martinell M, Dorkhan M, Carlsson A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6:361.

    Google Scholar 

Download references

Acknowledgements

We gratefully acknowledge Maria Sterner, Malin Neptin, and Jasmina Kravic for their technical assistance, sampling, and organisation of data. We also thank all the women participating in the study.

Funding

Open access funding provided by Lund University. The study was supported by grants from the Research Funds of Skåne University Hospital and the Skåne County Council’s Research and Development Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author information

Affiliations

  1. Genomics, Diabetes and Endocrinology, Department of Clinical Sciences, Lund University, Malmö, Sweden

    Rashmi B. Prasad, Karl Kristensen, Anastasia Katsarou & Nael Shaat

  2. Department of Obstetrics and Gynaecology, Skåne University Hospital, Malmö, Sweden

    Karl Kristensen

  3. Department of Endocrinology, Skåne University Hospital, 205 02, Malmö, Sweden

    Anastasia Katsarou & Nael Shaat

Authors
  1. Rashmi B. Prasad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karl Kristensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anastasia Katsarou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nael Shaat
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

RBP and NS designed the study. RPB and NS wrote the first draft, reviewed and edited the manuscript. NS supervised the study. RBP performed the statistical analysis. AK and KK reviewed and edited the manuscript. NS is the guarantor of this work. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Nael Shaat.

Ethics declarations

Ethics approval and consent to participate

The study was approved by the Ethics Committee of Lund University (LU 259-00) and written informed consent was obtained from all women included in the study. The authors confirm that all methods were carried out in accordance with the Declaration of Helsinki.

Consent for publication

Not applicable.

Competing interests

The authors declare that there is no conflict of interest associated with this manuscript.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Prasad, R.B., Kristensen, K., Katsarou, A. et al. Association of single nucleotide polymorphisms with insulin secretion, insulin sensitivity, and diabetes in women with a history of gestational diabetes mellitus. BMC Med Genomics 14, 274 (2021). https://doi.org/10.1186/s12920-021-01123-6

Download citation

Keywords

  • Prediction of diabetes
  • Gestational diabetes
  • Genetics of type 2 diabetes
  • Insulin sensitivity

BMC Medical Genomics

ISSN: 1755-8794

Contact us